Free Trial

Medpace (MEDP) Stock Forecast & Price Target

Medpace logo
$337.82 +0.07 (+0.02%)
(As of 11/25/2024 ET)

Medpace - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
6
Buy
5

Based on 11 Wall Street analysts who have issued ratings for Medpace in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 6 have given a hold rating, and 5 have given a buy rating for MEDP.

Consensus Price Target

$380.56
12.65% Upside
According to the 11 analysts' twelve-month price targets for Medpace, the average price target is $380.56. The highest price target for MEDP is $435.00, while the lowest price target for MEDP is $336.00. The average price target represents a forecasted upside of 12.65% from the current price of $337.82.
Get the Latest News and Ratings for MEDP and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medpace and its competitors.

Sign Up

MEDP Analyst Ratings Over Time

TypeCurrent Forecast
11/27/23 to 11/26/24
1 Month Ago
10/28/23 to 10/27/24
3 Months Ago
8/29/23 to 8/28/24
1 Year Ago
11/27/22 to 11/27/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
2 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$380.56$380.00$423.00$277.33
Forecasted Upside12.65% Upside15.07% Upside11.02% Upside0.51% Upside
Consensus Rating
Hold
Hold
Moderate Buy
Buy

MEDP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MEDP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medpace Stock vs. The Competition

TypeMedpaceMedical CompaniesS&P 500
Consensus Rating Score
2.45
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside12.65% Upside17,640.62% Upside6.38% Upside
News Sentiment Rating
Positive News

See Recent MEDP News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/25/2024Robert W. Baird
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$349.00 ➝ $354.00+4.81%
10/23/2024Baird R W
0 of 5 stars
E. Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
10/23/2024TD Cowen
4 of 5 stars
 Lower TargetBuy ➝ Buy$413.00 ➝ $372.00+13.81%
10/22/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
10/14/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$415.00 ➝ $397.00+13.99%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$404.00+16.54%
MUST-SEE: Everyone will be talking about this $2 trillion AI tech boom soon (Ad)

Amazon is making its biggest investment ever… $150 billion to be exact. And one company stands to benefit from this massive capital influx. This company could deliver a huge windfall for investors who get in before this story hits the mainstream, which could happen at any time.

Don't miss out... Click here to reveal Amazon’s Secret Partner.
9/27/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Sourbeer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$420.00 ➝ $350.00+7.28%
9/25/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$415.00 ➝ $345.00-3.04%
7/24/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$395.00 ➝ $336.00-11.53%
7/24/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$464.00 ➝ $432.00+20.91%
5/28/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$435.00+11.38%
5/8/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUpgrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:31 AM ET.


MEDP Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Medpace is $380.56, with a high forecast of $435.00 and a low forecast of $336.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.

According to analysts, Medpace's stock has a predicted upside of 12.65% based on their 12-month stock forecasts.

Over the previous 90 days, Medpace's stock had 4 downgrades by analysts.

Medpace has been rated by research analysts at Baird R W, Jefferies Financial Group, Redburn Atlantic, Robert W. Baird, TD Cowen, Truist Financial, UBS Group, and William Blair in the past 90 days.

Analysts like Medpace less than other "medical" companies. The consensus rating for Medpace is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MEDP compares to other companies.


This page (NASDAQ:MEDP) was last updated on 11/26/2024 by MarketBeat.com Staff
From Our Partners